STOCK TITAN

Merck & Co - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.

Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.

Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.

Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.

Rhea-AI Summary
New 10-year data on GARDASIL 9 vaccine shows no cases of certain HPV-related diseases in boys and girls vaccinated at ages 9-15 years. Antibody responses remained strong at 10 years. No serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Merck executives to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
Rhea-AI Summary
Merck's Dr. Marjorie Green to speak at Citi BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
Rhea-AI Summary
Merck initiates Phase 3 clinical program for MK-0616, an oral PCSK9 inhibitor, for the treatment of hypercholesterolemia. Phase 2b results showed significant LDL cholesterol reduction. Program plans to enroll approximately 17,000 participants across three global studies. Positive potential for MK-0616 to provide an important option for patients. No oral PCSK9 inhibitors currently available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
-
Rhea-AI Summary
Merck and Eisai provide update on Phase 3 trial for KEYTRUDA and LENVIMA combination in head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
Rhea-AI Summary
LYNPARZA combination approved in Japan for BRCA-mutated castration-resistant prostate cancer with distant metastasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
Rhea-AI Summary
WELIREG shows positive Phase 3 results in RCC trial with statistically significant improvements in PFS and ORR compared to everolimus. OS results inconclusive. Safety profile consistent with previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Merck & Co., Inc. - Dr. Rodney Finalle, a pediatrician and global director of medical affairs, shares his personal journey as a member of the LGBTQ+ community and the support he received from his workplace and community. Merck's partnership with a program matching professionals with nonprofit boards allowed Finalle to join the board of a local LGBTQ+ community center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
Rhea-AI Summary
Merck & Co., Inc. - Alaska partners with University of Alaska and drone provider to demonstrate drone delivery of medicines to remote villages, showcasing innovative solutions for increasing access to lifesaving pharmaceuticals in extreme weather and terrain. The project aims to expand access to medicines in remote areas, addressing the challenges faced by people living in Alaska's 240 remote villages and communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Merck & Co

NYSE:MRK

MRK Rankings

MRK Stock Data

199.22B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
KENILWORTH